Carolyn Chalice Lamb, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Consumer Health Information | 1 | 2020 | 212 | 0.150 |
Why?
|
| Comprehension | 1 | 2020 | 617 | 0.120 |
Why?
|
| Brachytherapy | 1 | 2000 | 1247 | 0.100 |
Why?
|
| Matrix Metalloproteinase 9 | 3 | 2008 | 641 | 0.090 |
Why?
|
| Axilla | 1 | 2011 | 599 | 0.080 |
Why?
|
| Taxoids | 2 | 2002 | 671 | 0.080 |
Why?
|
| Prostate | 4 | 2005 | 1794 | 0.080 |
Why?
|
| Metalloproteases | 1 | 2008 | 61 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2008 | 471 | 0.080 |
Why?
|
| Internet | 1 | 2020 | 3074 | 0.080 |
Why?
|
| Breast Neoplasms | 6 | 2020 | 20914 | 0.080 |
Why?
|
| Prostatic Neoplasms | 5 | 2008 | 11211 | 0.070 |
Why?
|
| Phenanthridines | 1 | 2005 | 51 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2002 | 1708 | 0.060 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 1096 | 0.060 |
Why?
|
| Leucovorin | 2 | 2002 | 637 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1073 | 0.060 |
Why?
|
| Particle Accelerators | 1 | 2003 | 175 | 0.050 |
Why?
|
| Epidermal Growth Factor | 1 | 2005 | 703 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2002 | 236 | 0.050 |
Why?
|
| Radiotherapy | 2 | 2002 | 1533 | 0.050 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 368 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2002 | 1633 | 0.050 |
Why?
|
| Therapeutics | 1 | 2020 | 115 | 0.040 |
Why?
|
| Urologic Diseases | 1 | 2002 | 244 | 0.040 |
Why?
|
| Carcinoma | 1 | 1991 | 2385 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2003 | 552 | 0.040 |
Why?
|
| Cisplatin | 2 | 2002 | 1664 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 621 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 2 | 2002 | 2812 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2008 | 2267 | 0.040 |
Why?
|
| ADAM Proteins | 2 | 2008 | 246 | 0.040 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2002 | 4062 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2011 | 9305 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1998 | 404 | 0.030 |
Why?
|
| Radiometry | 1 | 2000 | 808 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2000 | 921 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 3766 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2005 | 3131 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 2287 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 1991 | 378 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2002 | 11626 | 0.020 |
Why?
|
| Language | 1 | 2020 | 1506 | 0.020 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 8660 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 148 | 0.020 |
Why?
|
| Dimerization | 1 | 2008 | 893 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2000 | 6037 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2008 | 2260 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2008 | 907 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1998 | 3700 | 0.020 |
Why?
|
| Benzophenanthridines | 1 | 2005 | 27 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2005 | 428 | 0.010 |
Why?
|
| Alkaloids | 1 | 2005 | 190 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 2936 | 0.010 |
Why?
|
| Mastectomy | 1 | 2011 | 1814 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1991 | 3493 | 0.010 |
Why?
|
| Tattooing | 1 | 2003 | 59 | 0.010 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 1167 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 805 | 0.010 |
Why?
|
| Mathematics | 1 | 2003 | 727 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3500 | 0.010 |
Why?
|
| Scattering, Radiation | 1 | 2003 | 496 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 976 | 0.010 |
Why?
|
| Gene Expression | 1 | 1994 | 7771 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2008 | 21904 | 0.010 |
Why?
|
| Mammography | 1 | 2011 | 2459 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2005 | 1223 | 0.010 |
Why?
|
| Female | 8 | 2020 | 385090 | 0.010 |
Why?
|
| Humans | 11 | 2020 | 752741 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2008 | 6352 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 14761 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2003 | 935 | 0.010 |
Why?
|
| Posture | 1 | 2003 | 962 | 0.010 |
Why?
|
| Gelatinases | 1 | 1998 | 93 | 0.010 |
Why?
|
| Male | 8 | 2008 | 354311 | 0.010 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 1998 | 131 | 0.010 |
Why?
|
| Collagenases | 1 | 1998 | 227 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 2289 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2005 | 1670 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2005 | 2087 | 0.010 |
Why?
|
| Survival Rate | 1 | 1991 | 12802 | 0.010 |
Why?
|
| Middle Aged | 6 | 2008 | 216054 | 0.010 |
Why?
|
| Cell Line | 2 | 2005 | 16004 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2002 | 58361 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1998 | 1796 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2003 | 1189 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 2485 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 3589 | 0.010 |
Why?
|
| Aged | 5 | 2002 | 165629 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1998 | 1800 | 0.010 |
Why?
|
| Rats | 2 | 2005 | 24248 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2008 | 11091 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 13441 | 0.010 |
Why?
|
| Basement Membrane | 1 | 1994 | 358 | 0.010 |
Why?
|
| Gels | 1 | 1994 | 425 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1994 | 894 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 3757 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1994 | 219 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 6920 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2008 | 7941 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2002 | 10914 | 0.010 |
Why?
|
| Adult | 4 | 2002 | 216658 | 0.010 |
Why?
|
| Heart | 1 | 2003 | 4458 | 0.010 |
Why?
|
| Neoplasms | 1 | 1998 | 21976 | 0.010 |
Why?
|
| Dogs | 1 | 1994 | 3915 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 12202 | 0.000 |
Why?
|
| Prognosis | 1 | 2008 | 29264 | 0.000 |
Why?
|
| Risk Assessment | 1 | 2008 | 23554 | 0.000 |
Why?
|
| Extracellular Matrix | 1 | 1994 | 1747 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 6233 | 0.000 |
Why?
|
| Young Adult | 1 | 2011 | 57267 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 20026 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9990 | 0.000 |
Why?
|
| Retrospective Studies | 1 | 1991 | 78758 | 0.000 |
Why?
|
| Kidney Neoplasms | 1 | 1998 | 4280 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 20346 | 0.000 |
Why?
|
| Animals | 2 | 2005 | 169600 | 0.000 |
Why?
|
| Time Factors | 1 | 1994 | 40195 | 0.000 |
Why?
|